Gloucester Gears Up for FDA Panel Vote on Lymphoma Drug – Xconomy
You can bet that the people who just put $29 million into Gloucester Pharmaceuticals a few days ago will be watching very closely today for signs they got their money’s worth. The Cambridge, MA-based biotech company will try to make its case today Read More
WASHINGTON (AP) — Federal health experts have voted in favor of an experimental cancer drug from Allos Therapeutics for patients with a rare form of cancer. A spokeswoman for the Food and Drug Administration says the agency’s panel of cancer Read More
Gloucester Pharmaceuticals likely made its venture capitalists some fast money today. The Cambridge, MA-based biotech company— which scored $29 million in venture capital last week —won an unambiguous vote of confidence today from an FDA advisory Read More
Millennium: The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark Read More
Cases of non-Hodgkin lymphoma have more than tripled in the last thirty years according to the latest Cancer Research UK figures published today. Overall the number of people diagnosed with the disease in Great Britain has risen from over 3,000 in Read More
